Background We aimed to assess whether interferon-γ release assays (IGRAs) can predict the development of active tuberculosis and whether the predictive ability of these tests is better than that of the tuberculin skin test (TST).
Introduction
A third of the world's population is estimated to be infected with Mycobacterium tuberculosis, 1 providing a very large reservoir for future active tuberculosis. The tuberculin skin test (TST) has traditionally been used to identify people with latent M tuberculosis infection who will benefi t from isoniazid preventive treatment. 2 Despite its usefulness and simplicity, the TST has limitationsits specifi city is aff ected by BCG vaccination and its predictive value for incident tuberculosis disease is low.
T-cell-based interferon-γ release assays (IGRAs) can also be used for the diagnosis of M tuberculosis infection, and have been available for the past decade. Two licensed IGRAs are commercially available: QuantiFERON TB Gold in tube (Cellestis, Carnegie, Victoria, Australia) and T-SPOT.TB (Oxford Immunotec, Abingdon, UK). Studies of these assays have been reviewed for their ability to identify latent infection and to diagnose active disease in various populations. [3] [4] [5] [6] [7] IGRAs, like the TST, are a surrogate marker for M tuberculosis infection, indicating a cellular immune response to recent or remote sensitisation. However, neither assay can distinguish between latent and active tuberculosis. 8 Nevertheless, use of IGRAs in tuberculosis programmes is encouraged in many countries with low or intermediate incidence. 9 The clinical benefi t of IGRAs can be proven only if individuals identifi ed as having latent tuberculosis infection by IGRA are at increased risk of active tuberculosis compared with test-negative individuals and if these individuals benefi t substantially from preventive treatment. TST positivity is a surrogate marker for risk of subsequent tuberculosis (with those testing positive having a relative risk of about 2), and TST-positive individuals benefi t from isoniazid preventive treatment. 2, [10] [11] [12] [13] [14] [15] To show equivalent or superior clinical value to TSTs, IGRAs should be assessed in various at-risk subgroups. Such longitudinal data are emerging, but have not been systematically reviewed.
We previously published systematic and narrative reviews on IGRA accuracy and performance in various subgroups. [4] [5] [6] [7] [8] We did a systematic review and subsequent meta-analysis to assess whether IGRAs can prospectively predict the development of active tuberculosis in individuals without active disease at baseline and whether that predictive ability is higher than that of the TST. Our secondary objectives were to compare rates of tuberculosis in IGRA-positive individuals with TSTnegative or TST-positive results who received isoniazid preventive treatment, to assess the eff ect of immunological pheno types of discordant-concordant TST and IGRA results at baseline on subsequent tuberculosis rates, to establish whether a gradient association exists between quantitative interferon-γ response and rates of progression to tuberculosis disease, and to assess estimates of false-positive or falsenegative IGRA results versus TST results.
Methods

Search strategy and study selection
We updated the database searches (with the same terms) that were done in previous systematic reviews [4] [5] [6] [7] [8] and searched PubMed, Embase, Biosis, and Web of Science for relevant IGRA studies (up to June 30, 2011 ) that reported data on IGRA predictive value in all settings. We reviewed citations of all original articles published in all languages. In addition to electronic database searches, we reviewed bibliographies of previous reviews and guidelines on IGRA and screened the citations of relevant original articles. We contacted experts to obtain relevant citations. No language restrictions were made and fulllength papers, conference proceedings, and abstracts were included. When necessary, we contacted authors of primary studies to obtain additional information.
Studies were eligible for inclusion if they were longitudinal studies of adults or children, with or without HIV, who were free of active disease at study baseline that specifi cally stated assessment of the predictive ability of IGRA as a primary objective, had any longitudinal study design (eg, prospective or retrospective cohort) in any setting (low-income, middle-income, or high-income country), and described either active or passive follow-up of patients for any duration. Index tests assessed were any IGRA for M tuberculosis infection (whole-blood ELISA, enzymelinked immunosorbent spot [ELISPOT], in-house laboratory-developed non-commercial assay, or the latest generation of commercially licensed assays) that included at least one region of diff erence 1 (RD1) antigen (eg, early secretory antigenic target 6 [ESAT6], culture fi ltrate protein 10 [CFP10], Rv2654c [antigen TB7.7] ). The study endpoint assessed was active tuberculosis caused by M tuberculosis (we did not include studies that assessed non-tuberculous mycobacterium diseases), and the reference standard for the endpoint was any diagnosed incident active tuberculosis. Studies were included even if they did not stratify results into culture-confi rmed tuberculosis and clinically diagnosed tuberculosis.
Data extraction
Two reviewers (MXR and MP) independently assessed eligible articles for inclusion; disagreements were resolved by consensus. All articles included were assessed by a reviewer (MXR), who also extracted data, including study design, participants, country, period of recruitment, proportion of participant who had received BCG vaccination, IGRA methods (assay used, test version, cutoff -point used), TST methods (dose of purifi ed protein derivative [PPD] , cutoff -point used), and outcome data (eg, baseline TST and IGRA positivity rates, IGRA or TST concordance or discordance, and rates of progression to active tuberculosis). DL independently verifi ed the extracted data on studies' general characteristics, test characteristics, and main results.
Quality assessment
IGRA predictive value studies are not focused on diagnostic test accuracy. We therefore used a modifi ed Newcastle-Ottawa quality assessment scale for nonrandomised observational studies 16 rather than the quality assessment tool for diagnostic accuracy studies. 17 Studies were assessed for selection of study groups, comparability of study groups, and ascertainment of either the exposure or outcome of interest. Specifi c modifi cations were made to the selection and ascertainment of outcome items; high quality studies were those in which all cases of active tuberculosis were microbiologically confi rmed, IGRA results were not incorporated into the reference standard (ie, no incorporation bias), and clinicians who assessed resulting in further diff erential work-up bias (webappendix p 3). We did sensitivity analyses to explore the eff ect of key quality items on our main results.
Statistical analysis
The main outcome of interest was person-years incidence rates of disease (incidence density), stratifi ed by test 19 Because confounding is a concern in observational studies, we assessed whether adjusted IRR estimates were diff erent from unadjusted estimates. We had planned to use the best-reported adjusted estimate of relative risk from each study if diff erent from unadjusted estimates. However, most studies did not report adjusted estimates, and for those studies that did multivariable analyses, adjusted estimates were much the same as unadjusted estimates. Therefore, we used unadjusted estimates. Except when clearly indicated, all assays in the analyses were presented as IGRA irrespective of whether they were whole-blood ELISA or ELISPOT, inhouse or commercial.
Heterogeneity was assessed with the I² statistic and defi ned as low (I²≤25%), moderate (25%<I²≤50%), or high (I²>50%). 20, 21 We did not report pooled estimate measures or interpreted them cautiously when the I² value was greater than 25%. When heterogeneity was identifi ed, reasons were explored by calculation of eff ect measures stratifi ed by three prespecifi ed subgroups: key study quality items, country-level stratifi cations, and study-level stratifi cations. Country-level stratifi cations were high-income versus low-income or middleincome, 22 estimated tuberculosis incidence per 100 000 individuals, and HIV prevalence. Study-level stratifi cations were study population or cohort followed, retrospective or prospective design, proportion of participants with BCG scar, age strata (adult or children), inclusion of individuals with HIV, provision of isoniazid preventive treatment to individuals in the study, wholeblood ELISA versus ELISPOT assay, in-house or commercial assay, assay incubation period, and TST status of participants.
Diagnostic accuracy estimates for progression to disease were chosen as surrogates for patient-relevant outcomes. 23 A false-positive test result could result in unnecessary treatment in an individual who would not have progressed to tuberculosis disease, whereas a falsenegative result would mean progression to active tuberculosis disease that could have been prevented. TST=tuberculin skin test. PPD=purifi ed protein derivative. WBA=whole-blood assay. *All measured interferon-gamma. Studies done in Turkey, 27 Colombia, 28 and South Africa 38 described serial testing: interferon-γ release assay (IGRA) repeated at 6 months of follow-up, at 2 months of follow-up, and repeated for individuals with suspected tuberculosis, respectively. †Unit conversions given are equivalent to cutoff s defi ned in original papers: Hill et al 32 Bivariate random-eff ects regression was done to obtain global summaries of sensitivity and specifi city separately for studies that did IGRA (whole-blood ELISA or ELISPOT) and TST. We used Stata (version 10/MP) for all analyses.
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Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. MXR and MP had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Figure 1 shows the study selection process, reported according to PRISMA guidelines. 25 15 studies met our inclusion criteria (fi gure 1); [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] results of one study were described in two reports. 29, 41 Of the 15 included studies, four were done in low-income countries, fi ve in middleincome countries, and six in high-income countries; three had retrospective cohorts (table 1). The 15 included studies had a combined cohort size of 26 680 participants, with the study in South Africa 38 being the largest as of June 30, 2011 (11 988 person-years of follow-up).
All study cohorts were at high risk of tuberculosis (table 1) . Two studies 26, 33 followed up individuals with HIV (one of which, the study by Jonnalagadda and colleagues, 33 also studied infants who were followed up; main outcome results were stratifi ed into mothers and infants when possible), one 36 followed up a group of patients with silicosis, one 31 followed-up a cohort of asylum seekers, two 34, 40 followed up cohorts of health-care workers, one study 38 followed up adolescents in a high-incidence area, and eight [27] [28] [29] 30, 32, 35, 37, 39 followed up case contacts (table 1). All studies in high-income countries used data collected during routine care of patients. TST positivity was a prerequisite for IGRA testing in the studies by Kik and colleagues 35 and Harstad and colleagues. 31 Median study duration was 3 years (IQR 2-5). In three studies, 29, 31, 39 more than 20% of the cohort was lost to follow-up. In one study, 29 276 (72%) of 381 lost to followup were IGRA negative and had no information about development of tuberculosis. 0-76% of participants received isoniazid preventive treatment, which was not given to test-positive individuals in eight studies. 26, 28, 30, 32, 33, 35, 38, 40 Ten of 15 studies did a whole-blood ELISA, two of which 28, 30 used in-house assays and eight 26, 29, 31, 34, 35, [38] [39] [40] used the third-generation QuantiFERON-TB Gold in tube technology (table 2) . Six studies assessed the ELISPOT assay-three used in-house assays 27, 32, 37 and three used T-SPOT.TB. 33, 35, 36 All studies used incubation periods of less than 24 h, except for Doherty and colleagues 30 (5 days) and del Corral and colleagues (7 days). 28 11 of 15 studies included TST, 27, 29, 31, 32, 34, [35] [36] [37] [38] 40 but only eight 27, 29, 32, 34, [36] [37] [38] 40 reported results of the predictive value of TST (webappendix p 8). Table 3 shows key quality characteristics of included studies. Individuals selected seemed to be representative of specifi c high-risk groups of interest within the population (eg, case contacts or health-care workers); both IGRA-positive and IGRA-negative individuals came from the same high-risk for progression groups. However, studies varied in quality, especially with respect to ascertainment of incident tuberculosis and the potential for incorporation and diff erential work-up biases. Only in eight studies 29, [34] [35] [36] [37] [38] [39] [40] were at least half the active tuberculosis cases microbiologically confi rmed (webappendix p 5). In seven studies, 26, 29, 31, 35, [38] [39] [40] positive IGRA results were incorporated in the case defi nitions of active tuberculosis. Thus, IGRA-positive individuals were more likely than were IGRA-negative individuals to be investigated for tuberculosis or diagnosed with tuberculosis.
Nine studies 27, 28, [32] [33] [34] [35] [36] [37] [38] 45 reported incidence rates per person-time of follow-up (all of which except Kik and colleagues 35 reported rates stratifi ed by IGRA status), the remaining six reported cumulative incidence risk IGRA positive and negative from same source population 9 6
Assay described in detail 9 6 Active tuberculosis excluded at baseline* 8 4
Methods Study follow-up at least 1 year 9 6
≥80% of cohort followed up** 9 4
Outcome reported as incidence rate and rate ratio (person-time incidence) † † 8 1 *Studies in Germany, 29 Japan, 39 Kenya, 33 and Norway 31 did not clearly report whether active tuberculosis was adequately excluded at baseline. †Not assessed-studies reported that participants were screened for tuberculosis symptoms and signs, and that only those with a positive screen were investigated further for tuberculosis with methods that may or may not have included smear, culture, or both. ‡Incorporation bias (Austria, 26 Japan, 39 Norway, 31 Germany, 29 India, 34 South Africa, 38 Portugal 40 ) and not reported (Netherlands 35 ). ‡No or poor adjustment of confounders (Ethiopia, 30 The Gambia, 32 Turkey [isoniazid preventive treatment only], 27 Austria, 26 Colombia, 28 Norway, 31 Kenya, 33 India, 34 and South Africa 38 ). §For ascertainment of any health complaint that could have been active tuberculosis: Turkey, 37 China, 36 Colombia (home visits), 28 Senegal (home visits), 37 and The Gambia 22 (home visits). Studies without active follow-up include the studies done in Kenya 33 and India, 34 which relied on self-reports, tuberculosis subsequently confi rmed for nine of 14 in the Indian study. ¶Incorporation bias (Austria, Japan, Norway, Germany, South Africa, Portugal) and not reported (Netherlands). ||More than 50% cases culture-confi rmed (Senegal, 37 China, Netherlands, Japan, Germany, South Africa, India, and Portugal). **Inadequate follow-up of cohort or poor description for three high-income countries-Japan (55%), Norway (cannot estimate), Germany (70%, about 70% of whom were IGRA negative). † †Cumulative incidence and risk ratios reported (Ethiopia, and all six studies done in high-income countries). (webappendix p 5). Tuberculosis rates in IGRA-positive individuals were 4-48 cases per 1000 person-years, whereas rates in IGRA-negative individuals were 2-24 cases per 1000 person-years during a median period of observation of 4 years (IQR 2-6; fi gure 2). 33, 34 None of the studies reported rates of tuberculosis in IGRApositive individuals, with both TST-negative and TSTpositive results, who were given preventive treatment.
We compared unadjusted cumulative incidence risk ratios (RR) estimates because adjusted estimates were not available for most studies. The pooled RR for IGRApositive results was 3·54 (95% CI 2·23-5·60), but heterogeneity was high (fi gure 3).
Stratifi cation of studies by whether incorporation bias or diff erential work-up bias were or were not possible yielded a subgroup RR in the possibly biased studies higher than that in the subgroup of those in which such bias was not possible (fi gure 3). Studies with possible incorporation or diff erential work-up bias were therefore omitted from the rest of the review's main outcomes.
Although we had planned to explore heterogeneity by study characteristics, after exclusion of studies with possible incorporation or diff erential work-up biases, which included all those from high-income countries and with low national tuberculosis incidence, we were left with eight studies, 27, 28, 30, [32] [33] [34] 36, 37 all from low-income or middle-income countries. For these studies, we detected no statistical diff erence across strata for country-level subgroups (World Bank income classifi cation, tuberculosis case-detection rate, and HIV prevalence) or study-level subgroups (tuberculosis case contacts vs other cohorts, prospective vs retrospective study, BCG scar, children vs adults, any individuals with HIV in cohort, any isoniazid preventive treatment given, whole-blood ELISA vs ELISPOT assay, in-house vs commercial assay, and assay incubation period; data not shown).
In seven studies 27, 28, [32] [33] [34] 36, 37 reporting tuberculosis incidence rates stratifi ed by IGRA status, individuals with positive IGRA results at baseline had a higher incidence of active tuberculosis than did those with negative results (n=9530; fi gure 4). For three studies, 34, 36, 37 the pooled IRR in microbiologically confi rmed tuberculosis cases was higher (3·5, 95% CI 1·3-10·0) than for all cases of tuberculosis diagnosed (2·2, 1·1-4·5), but the diff erence was not signifi cant. In fi ve studies that reported results of multivariable analyses, 27,32,33,36,37 the adjusted IRR were much the same as the crude IRR (webappendix p 6).
Five studies 27,32,36-38 without biases in incorporation or diff erential work-up stratifi ed tuberculosis incidence by IGRA and TST results status at baseline. All studies used 0·1 mL of 2TU PPD RT23, but diff erent cutoff s for positivity were selected in these studies, according to national guidelines. Relative risks were stratifi ed by TST cutoff , when possible. The IRR of incident tuberculosis in test-positive individuals compared with test-negative individuals was slightly higher for IGRA than for the TST, but was not signifi cant because of overlapping CIs (fi gure 5).
Assessment of discordant results can help to fi nd out whether IGRAs are better than TST in the prediction of 32 The Gambia 9·24 (3·80-14·60) Bakir et al (2008) 27 Turkey 20·50 (10·20-36·70) del Corral et al (2009) 28 Colombia 7·70 (5·10-11·30) Lienhardt et al (2010) 37 Senegal 14·40 (8·40-23·00) Leung et al (2010) 36 China 32·00 (17·80-52·30) Jonnalagadda et al (2010) 33 Kenya (mothers) 42·00 (15·00-91·00) Jonnalagadda et al (2010) 33 Kenya (infants) 48·00 (16·00-112·00) Joshi et al (2011) 34 India 3·69 (1·66-8·21) Mahomed et al (2011) 38 South Africa 6·40 (4·50-8·70)
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Country
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Hill et al (2008) 32 The Gambia 5·00 (1·90-8·10) Bakir et al (2008) 27 Turkey 6·00 (1·60-15·40) del Corral et al (2009) 28 Colombia 4·10 (1·70-8·50) Lienhardt et al (2010) 37 Senegal 6·90 (2·50-14·90) Leung et al (2010) 36 China 7·10 (0·90-25·50) Jonnalagadda et al (2010) 33 Kenya (mothers) 16·00 (3·00-47·00) Jonnalagadda et al (2010) 33 Kenya (infants) 24·00 (5·00-69·00) Joshi et al (2011) 34 India 3·38 (1·69-6·76) Mahomed et al (2011) 38 South Africa 2·20 (1·20-3·80)
Figure 2: Unadjusted incidence rates for all tuberculosis diagnoses stratifi ed by interferon-γ release assay (IGRA) status
Incidence rate estimates are per 1000 person-years from individual studies that provided person-time data stratifi ed by IGRA status at baseline. 35 Netherlands 1·40 (0·34-5·74) Yoshiyama et al (2010) 39 Japan 6·74 (3·63-12·52) Harstad et al (2010) 31 Norway 18·76 (2·36-149·22) Diel et al (2010) 29 Germany 148·36 (9·00-2446·45) Mahomed et al (2011) 38 South Africa 2·89 (1·55-5·41) Costa et al (2011) 40 Portugal 32 The Gambia 1·84 (0·79-4·31) Bakir et al (2008) 27 Turkey 3·80 (1·22-11·86) del Corral et al (2009) 28 Colombia 1·89 (0·83-4·34) Lienhardt et al (2010) 37 Senegal 2·12 (0·85-5·34) Leung et al (2010) 36 China 3·82 (0·89-16·40) Jonnalagadda et al (2010) One study 35 did not report whether tuberculosis diagnoses methods included IGRA and was therefore included along with the six studies 26, 29, 31, [38] [39] [40] in which IGRA formed part of tuberculosis diagnoses methods and, therefore, incorporation bias could not be ruled out. Data from Kenya has been stratifi ed into HIV-exposed infants and their mothers who had HIV. 33 Pooled risk ratio (RR) estimate with Netherlands T-Spot.TB results (rather than QuantiFERON Gold in tube): RR=3·61 (95% CI 2·29-5·69), I²=67·4%, p=0·005. tuberculosis disease. 50 Four studies 27, 32, 34, 37 further explored rates of tuberculosis in paired concordant and discordant TST and IGRA results (table 4). Rates of tuberculosis were slightly higher in discordant pairs when IGRA was positive than in pairs when TST was the positive test; however, the association with incident active tuberculosis in the individual studies was weak (table 4) .
With a 7 day whole-blood ELISA, one study 28 assessed whether an exposure-gradient relation existed between baseline quantitative IGRA strata and subsequent rates of tuberculosis (webappendix p 7). Rates across the three highest strata were much the same and the CIs overlapped (incidence of 7 cases per 1000 person-years [95% CI 2·6-15·2] for 22-99 pg/mL, 6·7 [3·4-11·7] for 100-999 pg/mL, and 7·7 [5·1-11·3] for ≥1000 pg/mL); the incidence per 1000 person-years in the lowest stratum was 4·1 (1·7-8·5).
Three studies 27, 34, 37 assessed whether baseline median IGRA responses in individuals who subsequently developed tuberculosis were higher than responses in those who did not develop tuberculosis but had positive tests. In one study, 37 median responses were 250 spotforming cells (SFC) per million peripheral blood mononuclear cells (PBMC) in individuals who subsequently developed tuberculosis and 50 SFC per million PBMC in those who did not develop tuberculosis (p=0·02). By contrast, two studies 27, 34 noted no diff erences in median responses in individuals who developed tuberculosis compared with those who did not.
Findings from seven 27, 29, 31, 35, 37, 38, 40 of 11 studies that assessed IGRA and TST suggest that the proportion of IGRApositive participants who scored positive at the initial baseline visit might be lower than in those who were TSTpositive (at investigator-selected cutoff s; webappendix p 9).
For studies that used the ELISPOT assay, the sensitivity for developing active tuberculosis was 72% (95% CI 58-82) and specifi city was 50% (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) . 27, 32, 36, 37 Estimates for TST in those same studies were 72% (58-83) and 41% . 27, 32, 36, 37 However, estimates for both tests were imprecise. On the basis of these estimates, the falsepositive rate for the ELISPOT and TST were much the same-50% (95% CI 42-59) for ELISPOT and 59% (46-70) for TST (false-positive rate=100-specifi city). Falsenegative rates for the two tests were also similar. An estimate for studies that used the whole-blood ELISA was available from only two studies that were possibly not subject to incorporation or work-up bias. 28, 34 In one study, 28 which used a 7 day whole-blood ELISA assay, sensitivity was 79% (95% CI 61-91) and specifi city was 34% (32) (33) (34) (35) (36) , but in the other study, 34 which used an assay with a shorter incubation, reported sensitivity was 43% (18-72) and specifi city was 59% (55) (56) (57) (58) (59) (60) (61) (62) .
Discussion
The strength of the association between positive IGRA results and development of active tuberculosis in the studies identifi ed was weak to moderate, with relative risks of about 2-3. The incidence of tuberculosis, even in IGRA-positive individuals, was low, suggesting that most IGRA-positive individuals did not progress to tuberculosis disease during follow-up. This fi nding is similar to that for TST in this meta-analysis and in historical studies. 14 Thus, the most important fi nding in this review is that no available tests for latent M tuberculosis infection have high prognostic value.
However, in some populations the proportion of IGRA-positive individuals might generally be lower than the proportion of TST-positive individuals (as shown in seven of 11 studies assessed). This occurrence could be because of either higher IGRA specifi city for M tuberculosis infection or lower sensitivity than with TST. Higher specifi city would suggest that even though Whole-blood ELISA del Corral et al (2009) 28 Colombia 1·82 (0·80-4·20) Lienhardt et al (2010) 37 Senegal 2·00 (0·84-5·41) Jonnalagadda et al (2010) 34 India 1·09 (0·31-3·58) Subtotal (l 2 =0·0%, p=0·910) 1·82 (1·11-2·97)
Overall (I 2 =0·0%, p=0·876) 2·10 (1·42-3·08) ELISPOT Hill et al (2008) 32 The Gambia 1·90 (0·80-4·50) Bakir et al (2008) 27 Turkey 3·41 (1·08-10·70) Leung et al (2010) 36 China 32 The Gambia 2·10 (0·89-5·11) Lienhardt et al (2010) 37 Senegal 1·40 (0·48-4·74) Leung et al (2010) 36 China 1·64 (0·53-5·02) Joshi et al (2011) 34 India 1·05 (0·30-3·48) Subtotal (l 2 =0·0%, p=0·830) 1·60 (0·94-2·72) 32 The Gambia 1·90 (0·80-4·50) Bakir et al (2008) 27 Turkey 3·41 (1·08-10·70) Lienhardt et al (2010) 37 Senegal 1·81 (0·66-5·70) Leung et al (2010) 36 China 4·50 (1·03-19·68) Joshi et al (2011) 34 India 1·09 (0·31-3·58) Subtotal (l 2 =0·0%, p=0·568) 2·11 (1·29-3·46)
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Bakir et al (2008) 27 Turkey 2·65 (0·72-14·62) Lienhardt et al (2010) 37 Senegal 1·26 (0·37-4·29) 36 China 1·03 (0·33-3·15) Joshi et al (2011) 34 India 1·64 (0·47-7·16) Subtotal (l 2 =0·0%, p=0·789) 1·43 (0·75-2·72)
Country
Incidence rate ratio (95% CI) 0·2 1 20
Figure 5: Unadjusted incidence rate ratios for positive versus negative test result, by test type
Tuberculin skin test (TST) is stratifi ed by cutoff for studies that provided values in the original paper or on request. TST (10)=TST more than 10 mm. TST (5)=TST more than 5 mm.
use of both TST and IGRA is imperfect for informing a decision about who should receive preventive treatment, the number of individuals identifi ed for preventive treatment could be less with IGRA than with TST because fewer people are IGRA-positive than are TSTpositive. This characteristic of IGRAs might be useful in settings where TST specifi city is compromised by crossreactivity with environmental mycobacteria, BCG vaccination after infancy, or multiple BCG vaccinations. 51 In such settings, TST-positive and IGRA-negative discordance is likely to be common. As noted by Zwerling and colleagues, 5 high reversion rates of IGRA are common in settings with both low and high tuberculosis incidence, which might contribute to the low proportion of IGRA positivity (compared with TST) in many studies.
We had planned to explore heterogeneity by study characteristics. However, stratifi cation by studies with possible incorporation or diff erential work-up biases, left us with eight studies with a statistically homogeneous pooled estimate. Further assessment of these remaining studies did not show any statistically signifi cant diff erences across subgroup strata. Studies that use routine care data, from mostly high-income countries where commercial IGRA are already included in tuberculosis guidelines, are likely to report results that are in favour of IGRA. Although assessment of the tests in routine practice should be encouraged, the potential issues of incorporation bias or diff erential work-up should be anticipated early and be mitigated either in study design or at analysis. In the excluded studies, incorporation bias would have been mitigated if a defi nite diagnosis of incident tuberculosis was made for all cases on the basis of microbiological methods instead of diagnoses that relied on subjective clinical interpretation (unblinded to IGRA results). Complete and identical diagnostic work-up of all participants who entered followup, index-test positive and negative, would mitigate diff erential work-up bias. 52 Overall, most of the studies did not fully answer the question of whether IGRA, as a surrogate marker for future risk, can predict subsequent active tuberculosis. They merely showed a slight positive association between initial positive IGRA results and subsequent tuberculosis. Most studies were likely to yield exaggerated results in favour of a positive association largely because of ascertainment bias of active tuberculosis and by not fully accounting for other risk factors for tuberculosis. Furthermore, no studies assessed the ability of IGRA to adequately discriminate and therefore predict individuals at risk of developing disease from those not at risk. Discriminatory ability, rather than association, is of primary interest in predictive studies of disease. One measure of association does not imply that the new test can accurately discriminate individuals at risk of disease and those who will not develop disease. [53] [54] [55] [56] This fact is widely acknowledged in biomarker studies related to cancer and cardiovascular epidemiology. [56] [57] [58] Perfect discrimination will occur only when the distribution curves of the marker in individuals with disease versus individuals without disease do not overlap. 56 One marker or test has to be strongly associated with disease to be useful for disease prediction. 53, [56] [57] [58] A possible reason could be that even strongly associated risk factors or markers (eg, TST or IGRA) can perform poorly as tests of disease prediction if little variation exists in exposure (eg, high tuberculosis infection) within the population being studied. 53, 55 A biomarker such as interferon-γ could indicate M tuberculosis sensitisation (rather than disease) but might not, on its own, be adequate to predict active tuberculosis disease, especially in countries with a high burden and rates of reinfection. Interferon-γ might be necessary but not suffi cient on its own for prediction of disease. This fi nding is probably true even when interferon-γ is regarded as a correlate of protection in vaccine studies. 59 Interferon-γ alone might not be suffi cient as a biomarker because antigen-specifi c interferon-γ response is elicited in almost all stages of the tuberculosis spectrum. 60, 61 Therefore, the identifi cation of more predictive biomarkers is important, as is measurement of an array of biomarkers or incorporation of biomarkers with other known risk factors into a composite scoring system. 63 and the discriminatory incremental yield of new tests to existing clinical algorithms, before predictive ability is declared.
As discussed elsewhere, 64 another possible explanation for the poor predictive ability of existing tests for latent M tuberculosis infection is that a single or cross-sectional TST or IGRA result cannot resolve the underlying phenotypes because they do not capture information about when infection occurred and how the infection was fully, partly, or not eliminated by the host. All but two studies 27, 28 included in this review reported results of only one IGRA or TST test at baseline. Serial IGRA testing might show interesting underlying phenotypes that have diff erent histories and trajectories. 65 Without serial testing, the underlying phenotypes are not distinguishable, undermining the predictive value of a single test result.
Our systematic review had limitations. Data included in our review did not allow for formal assessment of publication bias with methods such as funnel plots or regression asymmetry tests. We, therefore, assume some degree of publication bias is likely because the number of studies of IGRA is rapidly increasing and new studies will soon become available-we are aware of at least three ongoing studies (in South Africa [NCT00463086], 66 Zambia [ZAMSTAR; ISRCTN36729271 ], 67 and the UK 44 ) that could not be included. Anecdotal reports exist of unpublished negative studies of IGRA-many (about 50%) IGRA studies have some industry involvement or support, 5 meaning that studies with negative fi ndings might not be published (or publication might be delayed). Data used to obtain our main summary measures were restricted to low-income to middle-income countries, which largely limits interpretation to those settings or similar individuals in high-income countries. IGRAs might have superior predictive ability in high-income settings with low tuberculosis incidence, but we were unable to identify this eff ect because of likely incorporation or work-up biases. A meta-analysis of individual patientdata would have allowed for a multivariable assessment of discriminatory value and better adjustment of confounding, and thus provide a better interpretation of available data, but this was not possible. Although inclusion of non-commercial IGRAs might be a limitation of our analysis, the inclusion of all studies of RD1-based assays enabled the most comprehensive synthesis of IGRA predictive ability to date.
Further research is needed to identify more predictive biomarkers to improve existing tests for latent M tuberculosis infection. Indeed, the revised Global Plan to Stop TB (2011-15) has set 2015 as the goal for such predictive tests. 68 Until then, the following strategies might be useful to improve the predictive value of existing tests: testing only those individuals at high risk of tuberculosis; serial testing to identify new infections (ie, conversions); incorporation of biomarkers with known risk factors (age, recent exposure, HIV infection, etc) into risk prediction models; and use of a higher cutoff for prediction of disease (as compared with diagnosis).
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Confl icts of interest
Assessment of whether
IGRA results were incorporated into the diagnosis of active TB during follow-up.
Whether methods to
exclude TB included microbiological tools (smear and/or culture)
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Only studies that reported TST results and/or provided additional information upon request are shown. †The TST positive sample is not restricted to those with both TST and IGRA results. ‡The Netherlands and Norway studies used TST (cutoffs 5mm and 6mm) as an inclusion criterion to the study. All participants will be TST positive at those thresholds. * Indicates author selected cutoff reported in paper. Income classification key: LIC=Low Income Country, MIC=Middle Income Country, HIC= High Income Country. Cutoffs used in studies are indicated in bold.
